Summary
Drug discovery involves various steps and is a long process being even more demanding for complex diseases such as cancer. Tumors are ensembles of subpopulations with different mutations, require very specific and effective strategies. Conventional drug screening technologies may not be adequate and efficient anymore. Drug repositioning is a useful strategy to identify new uses for previously failed drugs. High throughput and deep sequencing technologies provide valuable support by yielding enormous amounts of “-omics” data and contribute to understanding the molecular mechanisms responsible for drug action. Computational methods coupled with systems biology represent a promising step to interpret pharmacogenomic data and establish strong connections with drug discovery. Genomic variations have been found to be linked with differential drug response among individuals. Large genome wide association studies are necessary to identify reliable connections between genomic variations and drug response since personalized medicine has been accepted as an important phenomenon in the drug discovery and development process post approval.
Similar content being viewed by others
Abbreviations
- ENCODE:
-
Encyclopedia of DNA elements
- GWAS:
-
Genome wide association studies
- OMIM:
-
Online mendelian ınheritance ın men
- R&D:
-
Research and development
- SNP:
-
Single nucleotide polymorphism
- WES:
-
Whole exome sequencing
References
Mullard A (2012) 2011 FDA drug approvals. Nat Rev Drug Discov 11:91–94
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715
Dopazo J (2013) Genomics and transcriptomics in drug discovery. Drug Discov Today pii:S1359–6446(13):00166–9
Stratton MR (2011) Exploring the genomes of cancer cells: progress and promise. Science 331:1553–1558
Hawkins RD, Hon GC, Ren B (2010) Next-generation genomics: an integrative approach. Nat Rev Genet 11:476–486
Auffray C, Chen Z, Hood L (2009) Systems medicine: the future of medical genomics and healthcare. Genome Med 1:2
Barabási AL, Gulbahce N, Loscalzo J (2011) Network medicine: a network-based approach to human disease. Nat Rev Genet 12:56–68
Moreau Y, Tranchevent LC (2012) Computational tools for prioritizing candidate genes: boosting disease gene discovery. Nat Rev Genet 13:523–536
Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673–683
Ekins S, Mestres J, Testa B (2007) In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 152:9–20
Dudley JT, Deshpande T, Butte AJ (2011) Exploiting drug–disease relationships for computational drug repositioning. Brief Bioinform 12:303–311
Aronson JK (2007) Old drugs–new uses. J Clin Pharmacol 64:563–565
Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 3:96ra77
Wu Z, Wang Y, Chen L (2013) Network-based drug repositioning. Mol BioSyst 9:1268
Feero WG, Guttmacher AE, Collins FS (2010) Genomic medicine—an updated primer. N Engl J Med 362:2001–2011
ENCODE Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489:57–74
Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, Mort M, Phillips AD, Shaw K, Stenson PD, Cooper DN, Tyler-Smith C, 1000 Genomes Project Consortium (2012) Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am J Hum Genet 91:1022–1032
Carbonell J, Alloza E, Arce P, Borrego S, Santoyo J, Ruiz-Ferrer M, Medina I, Jiménez-Almazán J, Méndez-Vidal C, González-Del Pozo M, Vela A, Bhattacharya SS, Antiñolo G, Dopazo J (2012) A map of human microRNA variation uncovers unexpectedly high levels of variability. Genome Med 4:62
Barabasi AL, Oltvai ZN (2004) Network biology: understanding the cell’s functional organization. Nat Rev Genet 5:101–113
Luo H, Chen J, Shi L, Mikailov M, Zhu H, Wang K, He L, Yang L (2011) DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res 39:W492–W498
Zhao S, Li S (2012) A co-module approach for elucidating drug-disease associations and revealing their molecular basis. Bioinformatics 28:955–961
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892
Creixell P, Schoof EM, Erler JT, Linding R (2012) Navigating cancer network attractors for tumor-specific therapy. Nat Biotechnol 30:842–848
Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel M, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander E, Golub TR (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935
Conflict of interest
The authors declare that they have no conflict of interest whatsoever.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kadioglu, O., Efferth, T. Contributions from emerging transcriptomics technologies and computational strategies for drug discovery. Invest New Drugs 32, 1316–1319 (2014). https://doi.org/10.1007/s10637-014-0081-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-014-0081-x